Kalaris Therapeutics (KLRS) Accumulated Depreciation (2019 - 2022)

Kalaris Therapeutics' Accumulated Depreciation history runs 4 years deep, the most recent figure standing at $1.0 million for Q4 2022.

• In Q4 2022, Accumulated Depreciation rose 257.3% year-over-year to $1.0 million; the TTM figure through Dec 2022 stood at $1.0 million (up 257.3% YoY), while the FY2022 annual figure was $1.0 million, up 257.3% from the prior year.
• Accumulated Depreciation for Q4 2022 stood at $1.0 million, up from $281000.0 in the prior quarter.
• The five-year high for Accumulated Depreciation was $1.0 million in Q4 2022, with the low at $19000.0 in Q4 2019.
• The 4-year median for Accumulated Depreciation is $186500.0 (2020), against an average of $349000.0.
• The sharpest annual moves came in 2020 and 2021: Accumulated Depreciation soared 384.21% in 2020, then jumped 205.43% in 2021.
• Kalaris Therapeutics' Accumulated Depreciation stood at $19000.0 in 2019, then jumped by 384.21% to $92000.0 in 2020, then surged by 205.43% to $281000.0 in 2021, then surged by 257.3% to $1.0 million in 2022.
• Business Quant data shows KLRS's Accumulated Depreciation at $1.0 million in Q4 2022, $281000.0 in Q4 2021, and $92000.0 in Q4 2020.